1.Bray, F, Ferlay, J, Soerjomataram, I, Siegel, R, Torre, L, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424.10.3322/caac.21492
2.Clarke, M, Collins, R, Darby, S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366 (9503): 2087–2106. doi: 10.1016/S01406736(05)67887-7.
3.Yarnold, J, Ashton, A, Bliss, J et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol 2005; 75 (1): 9–17. doi: 10.1016/j.radonc.2005.01.005.
4.START Trialists’ Group, Bentzen, S M, Agrawal, R K et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9 (4): 331–341. doi: 10.1016/S1470-2045(08)70077-9.
5.Hennequin, C, Dubray, B. [Alpha/beta ratio revisited in the era of hypofractionation]. Cancer Radiother 2013; 17 (5–6): 344–348. doi: 10.1016/jcanrad.2013.06.035.
6.Owen, J R, Ashton, A, Bliss, J M et al. Effect of radiotherapy fraction size on tumour control in patients with early stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006; 7 (6): 467–471. doi: 10.1016/S14702045(06)70699-4.
7.START Trialists’ Group, Bentzen, S M, Agrawal, R K et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371 (9618): 1098–1107. doi: 10.1016/S0140-6736(08)60348-7.
8.Whelan, T J, Pignol, J P, Levine, M N et al. Long- term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362 (6): 513–520. doi: 10.1056/NEJMoa0906260.
9.Borghero, Y O, Salehpour, M, McNeese, M D et al. Multileaf field-in-field forward- planned intensity-modulated dose compensation for whole-breast irradiation is associated with reduced contralateral breast dose: a phantom model comparison. Radiother Oncol 2007; 82 (3): 324–328. doi: 10.1016/j.radonc.2006.10.011.
10.Teh, A Y, Walsh, L, Purdie, T G et al. Concomitant intensity modulated boost during whole breast hypofractionated radiotherapy-a feasibility and toxicity study. Radiother Oncol 2012; 102 (1): 8995. doi: 10.1016/j.radonc.2011.10.015.
11.Scorsetti, M, Alongi, F, Fogliata, A et al. Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. Radiat Oncol 2012; 7 (1): 145. doi: 10.1186/1748-717X-7-145.
12.Teoh, M, Clark, C H, Wood, K, Whitaker, S, Nisbet, A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 2011; 84 (1007): 967–996. doi: 10.1259/bjr/22373346.
17.Formenti, S C, Gidea-Addeo, D, Goldberg, J D et al. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol 2007; 25 (16): 2236–2242. doi: 10.1200/JCO.2006.09.1041.
18.Chadha, M, Vongtama, D, Friedmann, P et al. Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer 2012; 12 (1): 57–62. doi: 10.1016/j.clbc.2011.09.002.
19.Goldstein, D, Bennett, B K, Webber, K et al. Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. J Clin Oncol 2012; 30 (15): 1805–1812. doi: 10.1200/JCO.2011.34.6148.
20.Jagsi, R, Griffith, K A, Boike, T P et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol 2015; 1 (7): 918–930. doi: 10.1001/jamaoncol.2015.2590.
21.Harris, J R, Levene, M B, Svensson, G, Hellman, S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 1979; 5 (2): 257–261. doi: 10.1016/03603016(79)90729-6.
22.McDonald, M W, Godette, K D, Whitaker, D J, Davis, L W, Johnstone, P A S. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys 2010; 77 (2): 523–530. doi: 10.1016/j.ijrobp.2009.05.042.
23.Ghannam, A A, Khedr, R A. An accelerated hypofractionated schedule with a daily concomitant boost after breast conservation surgery: the feasibility and toxicity. J Egypt Natl Canc Inst 2016; 28 (1): 39–44. doi: 10.1016/j.jnci.2016.01.002.
24.Fayers, P M, Aaronson, N K, Bjordal, K et al. The EORTC QLQ-C30 Scoring Manual, 3rd edition. Brussels: European Organisation for Research and Treatment of Cancer, 2001.
25.Mock, V, Dow, K H, Meares, C J et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 1997; 24 (6): 991–1000.
26.Versmessen, H, Vinh-Hung, V, Van Parijs, H et al. Health-related quality of life in survivors of stage I-II breast cancer: randomised trial of post-operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer 2012; 12 (1): 495.10.1186/1471-2407-12-495